Clinical Trial: A randomized, open-label, multicenter phase Ib/III clinical trial of trastuzumab regan combined with bevacizumab versus bevacizumab for first-line maintenance treatment of epithelial ovarian cancer (China)

China, Oct. 9 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A randomized, open-label, multicenter phase Ib/III clinical trial of trastuzumab regan combined with bevacizumab versus bevacizumab for first-line maintenance treatment of epithelial ovarian cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133918

Registration Time: 2026/10/09

Type: Interventional study

Primary Sponsor: Zhejiang Cancer Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=345935

Published by HT Digital Content Services with permission from Health Daily Digest....